Tarsons Products FY26 Consolidated Revenue Up 8%

FY26 Consolidated Revenue: ₹422.5 crores, up 7.7% from ₹392.4 crores in FY25
Q4FY26 Consolidated Revenue: ₹120.9 crores, up 7.3% from ₹112.7 crores in Q4FY25
Gross Margin: 67.1% in FY26 (10 bps improvement from 67.0% in FY25)

EBITDA: ₹117.9 crores in FY26, down 1.7% from ₹120.0 crores in FY25
EBITDA Margin: 27.9% in FY26 (270 bps decline from 30.6% in FY25)
Reported PAT: ₹14.3 crores in FY26 compared to ₹29.8 crores in FY25
Adjusted PAT (excluding one-time labor code impact): ₹15.5 crores in FY26, down 48.1% from ₹29.8 crores in FY25
Adjusted PAT Margin: 3.7% in FY26 (390 bps decline from 7.6% in FY25)
Cash PAT (PAT + Depreciation): ₹112.0 crores in FY26, up 21.4% from ₹92.3 crores in FY25

Statutory impact of new labor codes: ₹1.1 crores expense in FY26 (effective November 21, 2025)
FY25 included one-time expense of ₹9.3 crores for provision for damage to machinery during transit

Domestic business delivered 12% growth in Q4FY26 YoY
Overall business grew 7% during FY26, outperforming industry growth
Exports impacted in Q4FY26 due to geopolitical situation in Middle East causing disruption in transit time and container availability
Nerbe revenue aided by favorable foreign exchange movement

7 manufacturing facilities in West Bengal with total land area of 66,086 sq. mts.
Jangalpur: 47.9% revenue contribution (Owned, 15,142 sq. mts.)
Dhulagarh: 22.9% revenue contribution (Leased, 4,047 sq. mts.)
Panchla: 15.4% revenue contribution (Owned, 21,550 sq. mts.) - new facility
Amta: 1.0% revenue contribution (Owned, 24,280 sq. mts.) - new facility
Commercial supplies commenced from Panchla & Amta facilities in Q4FY26
Full commissioning expected by H1FY27

Mr. Aryan Sehgal, Promoter and Whole time Director, commented:

PAT decline primarily due to increased depreciation and higher finance costs from capitalization of new facilities at Panchla and Amta
Revenue contribution from new facilities will commence in FY27
Company positioned to accelerate growth through new customers, deeper client relationships, and scaled export business
Over four decades of customer relationships and brand equity
Committed to long-term growth prospects, continuing investment through current cycle
Positioning for sustainable growth over next three to five years

Net Profit Before Tax: ₹21.9 crores
Cash generated from Operations: ₹126.5 crores
Net Cash from Operating Activities: ₹118.5 crores (up from ₹114.2 crores in FY25)
Net Cash from Investing Activities: ₹(130.4) crores
Net Cash from Financing Activities: ₹8.9 crores
Cash flow from operations/EBITDA: 100.5% in FY26 (103.2% in FY25)

Leading Indian labware company with 40+ years experience
Designs, develops, manufactures, and markets laboratory consumables, reusables, and benchtop equipment
Products used across research organizations, academia, pharmaceutical companies, CROs, diagnostic companies, and hospitals
2,000+ SKUs across 350 product segments
6 vertically integrated manufacturing facilities in West Bengal
Pan-India distribution network
Global reach with products supplied to 40+ countries through 45+ distributors

Strong brand recognition with product brands like Maxipense, Spinwin, Cryochill
Pioneered first fully automated plant for manufacturing molecular biology consumables
In-house engineering team driving innovation
Quality Certifications: ISO 9001, 13485 & 14001
Manufacturing in clean aseptic environment (ISO 8 clean rooms)

Export operations include branded and ODM sales
ODM model involves independent design and development as per client requirements
Key overseas ODM client: Toei Kaisha
Export market expected to grow at 10% CAGR in developing markets

Sanjive Sehgal: Chairman & Managing Director (40+ years experience)
Aryan Sehgal: Promoter and Whole time Director (10+ years experience)
Suresh Prabhala: Non-Executive Director (Co-founder & Managing Partner at ADV Partners)
Ramanathan Subramanian Arun Kumar: Non-Executive Nominee Director (Partner & COO at ADV Partners)
Vinesh Mohan Kriplani: Independent Director (29 years tax and regulatory experience)
Dr. Monjori Mitra: Independent Director (Medical researcher in vaccines)
Divya Momaya: Independent Director (22+ years corporate governance experience)
Viresh Oberai: Independent Director (22+ years Tata Steel experience)

Santosh Agarwal: CFO & Company Secretary (21+ years experience, qualified CA & CS)